The US Environmental Protection Agency has given the go-ahead to Monsanto for its RNAi-based insecticide, the Atlantic reports. It adds that this is the first approved RNAi insecticide.

"I would put RNA in the suite of really advanced, next-generation technologies that are adding to the excitement from a research perspective," Robb Fraley, the chief technology officer at Monsanto, tells the Atlantic.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.